Human evidence record · NAD+

Six-hour intravenous NAD+ metabolome pilot

The study characterized metabolism/excretion during infusion; it was not designed to establish anti-ageing, energy or cognitive efficacy.

Quick read

Human evidence record

What this study tells us

This study compared groups, which is more informative than an uncontrolled report. The amount of confidence still depends on how the groups were formed, how outcomes were measured and how well bias was controlled.

Who was studied?

Adults receiving NAD+ or saline

How many?

n=11

What happened?

The study characterized metabolism/excretion during infusion; it was not designed to establish anti-ageing, energy or cognitive efficacy.

What stops us overclaiming?

Very small sample; pharmacokinetic/metabolomic study, not a therapeutic efficacy trial.

Need help with terms such as randomized, placebo, endpoint or sample size? Open the glossary →

Key result

The study characterized metabolism/excretion during infusion; it was not designed to establish anti-ageing, energy or cognitive efficacy.

Study details

Study designPilot controlled human infusion study

PopulationAdults receiving NAD+ or saline

Sample size11

RouteIntravenous infusion

Regimen / exposure750 mg NAD+ over 6 hours (~3 micromol/min)

Duration6 hours

ComparatorSaline control (3 participants)

Primary endpoint / questionPlasma/urine NAD+ metabolome and tolerability

Safety resultNo observable adverse events were reported in the NAD+ cohort during the infusion period.

Key limitationsVery small sample; pharmacokinetic/metabolomic study, not a therapeutic efficacy trial.

Registry / identifierDOI 10.3389/fnagi.2019.00257

Open NAD+ page →Open primary source →